Teva names Erez Vigodman as CEO


As expected, Teva (TEVA) has appointed board director Erez Vigodman as CEO to replace Jeremy Levin, who resigned in October.

Vigodman has been CEO of MA Industries, the world's largest generic agrochemical company, since 2010. He led the firm's return to profitability by improving its day-to-day operations and investing in organic growth.

Prior to that, Vigodman headed food company Strauss Group, whose sales doubled under his tenure.

The challenges he faces at Teva include Copaxone's upcoming patent expiration and the implementation of a $2B cost-reduction program.

Shares are -0.55% in Tel Aviv. (PR)

From other sites
Comments (1)
  • nicolò
    , contributor
    Comments (60) | Send Message
     
    How is Teva pipeline? Do they have potential blockbusters in phase 2 or 3?
    9 Jan 2014, 05:11 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs